Rhythm Pharmaceuticals Revenue and Competitors

Boston, MA USA

Location

#4333

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Rhythm Pharmaceuticals's estimated annual revenue is currently $5.9M per year.(i)
  • Rhythm Pharmaceuticals received $41.0M in venture funding in February 2017.
  • Rhythm Pharmaceuticals's estimated revenue per employee is $19,633
  • Rhythm Pharmaceuticals's total funding is $84M.

Employee Data

  • Rhythm Pharmaceuticals has 300 Employees.(i)
  • Rhythm Pharmaceuticals grew their employee count by 26% last year.

Rhythm Pharmaceuticals's People

NameTitleEmail/Phone
1
Chairman, President and CEOReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
Chief Human Resources OfficerReveal Email/Phone
4
VP Financial Planning and AnalysisReveal Email/Phone
5
Head PublicationsReveal Email/Phone
6
VP Clinical OperationsReveal Email/Phone
7
EVP, Head North AmericaReveal Email/Phone
8
EVP, Head North AmericaReveal Email/Phone
9
VP, Head Information TechnologyReveal Email/Phone
10
VP, Technical OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Rhythm Pharmaceuticals?

Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity. Rhythm's lead product candidate is setmelanotide, a first-in-class melanocortin-4 receptor (MC4R) agonist. Rhythm supports The Genetic Obesity Project (GeneticObesity.com) and the GO-ID Genotyping Study (GeneticObesityID.com).

keywords:Biotechnology,Enterprise Software,Healthcare,Human Resources Hr,Pharmaceuticals

$84M

Total Funding

300

Number of Employees

$5.9M

Revenue (est)

26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Rhythm Pharmaceuticals News

2022-04-17 - Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ...

Needham & Company LLC dropped their price target on Rhythm Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating on the stock in a...

2022-04-13 - Rhythm Pharmaceuticals Announces New Employment ...

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company...

2022-04-06 - Rhythm Pharmaceuticals Optimizes Design of EMANATE and ...

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity.

2021-09-22 - Rhythm Pharmaceuticals : Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting

-- New subgroup analysis of Phase 3 data show setmelanotide achieved statistically significant weight loss and hunger reduction compared with placebo at 14 weeks in patients with Bardet-Biedl syndrome -- -- Efficacy results from complete topline analyses of Rhythm’s Phase 2 Basket Study show wei ...

2020-01-07 - Rhythm CEO Kei­th Gottes­di­ener hits the ex­it; Take­da sets up an AI dis­cov­ery pro­gram at MIT

→ Rhythm Phar­ma­ceu­ti­cals $RYTM CEO Kei­th Gottes­di­ener is plan­ning to stay at the helm un­til the biotech com­pletes its new drug ap­pli­ca­tion, and then head out. He says it’s the right time to hand over the reins and the com­pa­ny plans to or­ga­nize a search for his re­place­ment. His ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$106.6M300-4%N/A
#2
$80.9M300-10%N/A
#3
$55.4M3016%$65M
#4
$53.5M3016%$65M
#5
$76.1M3032%N/A

Rhythm Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2010-09-09$40.0MAMPM Capital, New Enterprise AssociatesArticle
2012-06-05$9.5MUndisclosedArticle
2012-06-14$25.0MBMPM Capital, New Enterprise AssociatesArticle
2012-11-28$8.0MUndisclosedPfizer Venture InvestmentsArticle
2017-02-17$41.0MUndisclosedMultipleArticle